Article
Updates in the Treatment of Metastatic Colorectal Cancer
2023-05-01
Abstract excerpt
Molecular biomarker testing for all patients with metastatic colorectal cancer (CRC) has become increasingly important because identifying targetable alterations can lead to meaningful clinical benefits. At a minimum, testing should include RAS, BRAF mutational status, microsatellite instability status, HER2 expression, NTRK, and RET mutations. For HER2-amplified cancer, the NCCN Guidelines offer multiple treatmen...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 29a56de1-77f6-58dd-9ca6-8993f8f48aea
- DOI
- 10.6004/jnccn.2023.5012